Table 1.
Baseline Demographics, Disease Characteristics, and Previous Induction Regimensa
| Characteristic | Patients (n = 84) |
|---|---|
| Age, y | |
| Median | 73 |
| Range | 49-90 |
| Age group, n (%) | |
| ≥65 y | 67 (80) |
| ≥75 y | 37 (44) |
| Male gender, n (%) | 41 (49) |
| Race, n (%) | |
| White | 61 (73) |
| Black/African American | 13 (15) |
| Asian | 2 (2) |
| >1 Race selected | 1 (1) |
| Missing | 7 (8) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 8 (10) |
| Not Hispanic/Latino | 72 (86) |
| Not reported/unknown | 4 (5) |
| ISS stage at initial diagnosis, n (%) | |
| I | 22 (26) |
| II | 25 (30) |
| III | 29 (35) |
| Unknown | 8 (10) |
| Type of myeloma at initial diagnosis, n (%) | |
| Heavy chain | |
| IgG | 50 (60) |
| IgA | 16 (19) |
| IgD | 1 (1) |
| IgM | 1 (1) |
| Multiple | 7 (8) |
| Missing | 9 (11) |
| Light chain | |
| Kappa | 51 (61) |
| Lambda | 27 (32) |
| Multiple | 5 (6) |
| Missing | 1 (1) |
| Lytic bone disease, n (%) | 35 (42) |
| Extramedullary disease, n (%) | 6 (7) |
| Creatinine clearance,b mL/min | |
| Median | 69 |
| Range | 12-226 |
| Calculated creatinine clearance, n (%) | |
| <30 mL/min | 4 (5) |
| 30 to < 60 mL/min | 20 (24) |
| 60 to < 90 mL/min | 35 (42) |
| ≥90 mL/min | 17 (20) |
| Missing | 8 (10) |
| Concurrent medical conditions,c n (%) | 83 (99) |
| Hypertension | 48 (57) |
| Anemia | 37 (44) |
| Fatigue | 36 (43) |
| Renal/urinary disordersd | 34 (40) |
| Cardiac disordersd | 25 (30) |
| Insomnia | 25 (30) |
| Gastroesophageal reflux disease | 24 (29) |
| Constipation | 24 (29) |
| Back pain | 19 (23) |
| Nausea | 17 (20) |
| Peripheral edema | 17 (20) |
| Anxiety | 16 (19) |
| Hyperlipidemia | 15 (18) |
| Arthralgia | 14 (17) |
| Hypercholesterolemia | 13 (15) |
| Peripheral neuropathy | 11 (13) |
| Diabetes mellituse | 11 (13) |
| Induction regimen at the time of iCT to IRd, n (%) | |
| VRD | 71 (85) |
| VCD | 11 (13) |
| Other (VD; VR) | 2 (2) |
Abbreviations: iCT = in-class transition; IRd = ixazomib, lenalidomide, dexamethasone; ISS = International Staging System; VCD = bortezomib, cyclophosphamide, dexamethasone; VD = bortezomib, dexamethasone; VR = bortezomib, lenalidomide; VRD = bortezomib, lenalidomide, dexamethasone.
a
At enrollment (or initial diagnosis for ISS stage and type of myeloma).
b
Patient number totaled 76.
c
Occurring in ≥ 15% of patients and specific other comorbidities of clinical importance.
d
System organ class (other concurrent medical conditions listed by preferred term).
e
Included preferred terms of diabetes mellitus (n = 4) and type 2 diabetes mellitus (n = 7).